


PHARMACEUTICAL 2018

Aimmune Therapeutics Inc. Rank 121 of 342





PHARMACEUTICAL 2018

Aimmune Therapeutics Inc. Rank 121 of 342

The relative strengths and weaknesses of Aimmune Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aimmune Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Aimmune Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 148%, being 102% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	189,111
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,599
Liabilities, Non-Current	2,530
Other Assets	618
Other Compr. Net Income	-81
Other Expenses	56
Other Liabilities	0
Other Net Income	2,005
Other Revenues	0
Property and Equipment	17,205
Research and Development	89,325
Selling, General and Administrative Expense	43,949

Output Variable	Value in 1000 USD
Assets	206,934
Liabilities	29,129
Expenses	133,330
Revenues	0
Stockholders Equity	177,805
Net Income	-131,325
Comprehensive Net Income	-131,366
Economic Capital Ratio	148%

